INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients. [1] COPD, the fourth leading cause of death in the world, [2] represents an important public health challenge that is both preventable and treatable. Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population. [3] Background: Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world. Exacerbation of COPD has negative effect on quality of life. Therapeutic effect of nebulized antibiotics in pulmonary infections has been reported previously. Hence, we evaluated the effect of nebulized gentamicin in acute exacerbation of COPD (AECOPD).
Materials and Methods:
In this clinical trial study, 86 hospitalized patients with AECOPD were divided into two groups for using nebulized gentamicin twice daily (case group) and placebo (control group) for 5 days in addition to standard treatment. On admission and on the 6 th day, respiratory rate (RR), white blood cell (WBC), spirometry, and SPO 2 (arterial O 2 saturation by pulse oxymetry) were measured in groups. The severity of dyspnea was evaluated by the Medical Research Council scale. Results: In both groups, changes of SpO 2 , RR, forced an expiratory volume of first second (FEV1), and forced vital capacity (FVC) were significant during the times of intervention (P < 0.05). However, changes of FEV1 and FVC were significantly different between two groups (P < 0.05). So that increments of FEV1 and FVC were higher in the case group than control group. WBC decreased significantly in the case group (P < 0.05) compared to control group. There was no significant difference between groups in severity of dyspnea after intervention (P > 0.05). Conclusion: Treatment with Nebulized Gentamicin in AECOPD exacerbation resulted in further improvement of FVC and FEV1 on the 6 th day.
MATERIALS AND METHODS
This study was a double-blinded placebo-controlled clinical trial conducted on a sample of hospitalized patients with AECOPD. All patients older than 40 years and known case of COPD were included in the study. Patients with a history of heart failure (ejection fraction <40%), renal failure, ongoing ischemia (based on electrocardiography), hearing problems, lung cancer, lung abscess, bronchiectasis, lung resection surgery, and hypersensitivity to aminoglycosides were excluded. The sampling method was based on convenience sampling. The sample size was calculated based on the result of a pilot study to obtain a 95% of confidence and a power of 80% to see a difference between two groups equal to 60% of standard deviation in the mean increasing of forced expiratory volume (FEV) parameter during the intervention. The sample size obtained as 43 patients in each group. The study was approved by the Ethical Committee of the Shahrekord University of Medical Sciences and was registered at ClinicalTrials.gov, number IRCT2015081723659N1. Informed consent was obtained from all participants.
Participants were randomly assigned to two groups of placebo (control) and gentamicin (case). Both patients and investigators were blinded to study groups. In all patients after hospitalization, on admission, SpO 2 (oxygen saturation), respiratory rate (RR) and white blood cell (WBC) were measured and spirometry was performed. Patients in case group received gentamicin (Osveh factory, Iran) 80 mg (2 cc) plus 1 cc sodium chloride 0.9% nebulization [17] and patients in control group received 2 cc distilled water plus 1 cc sodium chloride 0.9% nebulization twice daily for 5 days were used. Both groups were under treatment with supplemental O 2 , tablet amoxicillin-clavulanic acid 625 mg every 8 h, capsule doxycycline 100 mg twice a day, salbutamol nebulization, ipratropium bromide nebulization, and tablet prednisolone 30 mg daily. On the 6 th day, RR, SpO 2 , WBC, and spirometry were repeated in two groups. Spirometry in all patients was done by spirometer custo vit m R 2010.
To evaluate the effect of treatment on dyspnea in both groups, the Medical Research Council (MRC) scale [ Table 1 ] was used. [10] The best value of forced vital capacity (FVC) and FEV of first second (FEV1) and FEV1/FVC ratio were recorded.
Data analysis
For continuous variables, data are given as means ± standard deviation (SD) and for categorical ones, as number with percent. Comparisons between two groups were done using the Chi-square or Fisher exact test for categorical variables and independent t-test for continuous ones. Paired -t-test was used for comparing the changes between two periods for continuous variables. Wilcoxon signed rank test was used to compare the severity of dyspnea before and after study. Statistical analysis was done by SPSS 16 (Version 16.0, 2007, SPSS Inc., Chicago, IL, USA). and P < 0.05 was statistically significant.
RESULTS
In this study, of 86 patients, 43 patients were included in the case and 43 patients in the control group. The age of patients in the case group was from 49 to 82 years with mean (SD) of 65.5 ± 9.7 years and in the control group from 43 to 89 years with mean of 66 ± 12 years (P = 0.82). 27 (62.8%) patients in the case group and 24 (55.8%) in the control group were female (P = 0.51). The height of patients in the case group was from 157 to 180 cm with mean of 167.2 ± 6.4 cm and in the control group from 156 to 180 cm with mean of 166.7 ± 7.4 cm (P = 0.75).
Mean of interested variables including SpO 2 , RR, FEV1, FVC, and WBC on the first and 6 th day of intervention are presented in Table 2 .
Changes of all variables except WBC after intervention were significant in the both groups. However, changes of SpO 2 and RR were not significantly different between two groups, but changes of FEV1 and FVC were significantly different between two groups, so that, increments of FEV1 and FVC were higher in the case group than control group. WBC decreased significantly in the case group, but it did not change in the control group.
Severity frequency of dyspnea in the case and control groups based on MRC scale was shown in Table 3 . Based on MRC scale, on the 1 st day, there were three patients in Grade 2, 17 patients in Grade 3, 15 patients in Grade 4, and eight patients in Grade 5 of dyspnea in the case group. In the control group, there were two patients in Grade 2, 15 patients in Grade 3, 21 patients in Grade 4 and 5 patients in Grade 5. There was no patient in Grade 1 in the both group on the 1 st day of intervention. On the 6 th day, there were twenty patients in Grade 1, 17 patients in Grade 2, six patients in Grade 3 of dyspnea in the case group. In the control group, there were 18 patients in Grade 1, 23 patients in Grade 2, two patients in Grade 3. There was no patient in Grade 4 and 5 in both groups after intervention. There was no significant difference between groups in severity of dyspnea on the 1 st day (P = 0.60) and 6 th day (P = 0.27). Wilcoxon signed rank test showed a significant reduction on the grade of dyspnea during the study [ Table 3 ].
DISCUSSION
Different studies have been done on the effect of nebulized antibiotics on different chronic lung diseases, but there are controversy results and the data are not conclusive to prove the therapeutic effect of this treatment. Our results showed strong association between treatment with nebulized gentamicin and better spirometric parameters (FVC and FEV1).
Bacterial infection is important etiology of AECOPD. In a clinical trial was done by Schienberg and Shore, treatment with tobramycin solution inhalation was associated with significant improvement in mean pulmonary total symptom severity score, a composite score that assesses the severity of cough, dyspnea, sputum production, fatigue, and wheezing in patients with severe bronchiectasis. [18] However, in our study, improvement of dyspnea in two groups was not different significantly. This may be due to different patients evaluated (COPD versus bronchiectasis). Similar to our study Murray et al., showed that nebulized gentamicin in non-CF bronchiectasis for 12 months had significant benefit in noncystic fibrosis bronchiectasis. [19] In another study, researchers demonstrated that long-term therapy with inhaled gentamicin could eradicate the infection or reduce the bacterial load, decrease the risk of subsequent infections and improve the quality of life in patients with non-CF bronchiectasis with a minimal risk of side effects. [14] In previous studies, the role of PA infection in AECOPD have been clarified. [8] [9] [10] [11] [12] [13] Although we did not check the sputum culture for detecting PA, beneficial effect of nebulized gentamicin may be due to therapeutic effect on PA.
CONCLUSION
Treatment with Nebulized Gentamicin in AECOPD exacerbation resulted in improvement of FVC and FEV1 on the 6 th day.
Limitations
The small sample size and short evaluation time could be a limitation of this study for more conclusions about the efficacy of gentamicin. In addition, the lack of microbiologic study of sputum in patients was another limitation to be able to discuss the PA infection.
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